FADS2 Genotype

If you eat the same salmon, walnuts, or flaxseeds as your neighbor, you might still end up with very different amounts of the long-chain omega-3s and omega-6s circulating in your blood. A meaningful slice of that difference is written into your FADS2 (fatty acid desaturase 2) gene, which dictates how efficiently your body converts the short-chain fats in food into the longer, more useful forms.

This is a one-time test of a fixed genetic variant. The result will not change over your lifetime, but it can reshape how you interpret your omega-3 index, your lipid panel, and how aggressively you may need to chase omega-3 intake from food or supplements.

What This Gene Actually Does

FADS2 codes for an enzyme called delta-6 desaturase, which sits at the gateway of long-chain polyunsaturated fat production. When you eat plant-based omega-3 (ALA from flax or walnuts) or omega-6 (linoleic acid from seed oils), this enzyme is one of the first to act on them, kicking off the chain reaction that produces EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), and arachidonic acid, the forms your cells, brain, and immune system actually rely on.

The most-studied common variants in the FADS cluster do not change the amino acid sequence of the enzyme. Instead, they are regulatory variants that affect how strongly the gene is read, through mechanisms like altered DNA methylation and transcription factor binding. Studies have found that one variant (rs174570) is linked to lower expression of FADS1 and FADS2 in the populations studied, though across different tissues FADS cluster variants can shift FADS1 and FADS2 expression in opposite directions. The practical upshot is that two people can eat identical diets and produce noticeably different amounts of long-chain fats.

How the Variants Reshape Your Fatty Acid Profile

The clearest, most consistent finding across studies is that certain FADS cluster genotypes produce a measurable drop in the long-chain fats most readers care about. In a Hispanic and Latino cohort, people with the TT version of rs174537 (a variant located just downstream of FADS1 that, because of tight genetic linkage across the FADS cluster, also affects FADS2 activity) had about 37% lower arachidonic acid and 23% lower EPA in plasma compared with those carrying the GG version. In pregnant women, minor-allele carriers across several FADS cluster variants showed lower arachidonic acid, EPA, and DHA in both blood and breast milk.

In European adolescents, rare alleles in the FADS gene cluster were tied to higher delta-6 desaturase activity but lower delta-5 activity, a fingerprint that shows the gene shifts the balance of which long-chain fats your body ends up with, not just the total amount. None of this means you cannot reach a healthy omega-3 level. It means the cost of getting there is higher for some people than others, and supplementing with preformed EPA and DHA may matter more than relying on plant-based ALA.

Heart and Lipid Risk

FADS cluster variants have been tied to blood lipid patterns across multiple populations and are among the strongest genetic signals linked to triglyceride levels. In Taiwanese adults with type 2 diabetes, the G allele of rs174602 was associated with lower LDL cholesterol. In an Indian cohort with type 2 diabetes, minor G allele carriers of rs174575 had worse lipid profiles and roughly three times higher diabetes risk than non-carriers. In Japanese and Mongolian cohorts, the FADS region rs174547 variant tracked with higher triglycerides and lower HDL.

In obese adults, the TT genotype of rs174583 was linked to higher triglycerides and larger waist circumference, with minor allele carriers showing higher odds of elevated triglycerides. These are observational findings, not personalized risk scores. They reflect a pattern: FADS2 variants nudge lipid metabolism in directions that interact with diet and metabolic health, rather than acting as a switch that guarantees disease.

Type 2 Diabetes and Metabolic Health

Several studies link FADS region variants to type 2 diabetes risk and insulin sensitivity. The rs174547 variant has been associated with diabetes risk in some cohorts, with the minor allele linked to lower desaturase activity. FADS cluster variants have also been linked to insulin sensitivity in children and adolescents with overweight or obesity, suggesting the gene's influence shows up early in metabolic life. It is worth noting that, despite these signals, FADS1-2-3 cluster variants have not reached genome-wide significance for type 2 diabetes or atherosclerotic cardiovascular disease risk in large-scale analyses. They are associated with cardiometabolic traits, not a confirmed driver of disease.

The link is not a one-way street. Diet quality has repeatedly been shown to blunt or amplify FADS2's effect on metabolic markers. Adherence to DASH, Mediterranean, and other high-quality eating patterns weakened the connection between rs174583 and adverse triglyceride, glucose, blood pressure, and insulin resistance readings in obese adults. Your genotype is a starting condition; your diet decides how much it actually shapes your numbers.

Pregnancy and Child Development

For people planning a pregnancy or currently pregnant, the FADS cluster carries weight. A Mendelian randomization study using a FADS region variant (rs174450, located in the neighboring FADS3 gene region and inherited together with FADS2 variants) found that each copy of the minor allele was associated with a shorter gestation by about 2.2 days, consistent with a role for long-chain omega-3s in pregnancy duration.

Maternal FADS2 genotype also seems to filter the benefit of prenatal DHA. In a follow-up of a randomized DHA supplementation trial, children of mothers with the TT genotype at rs174602 scored higher on cognitive and memory tests at age 5 if their mothers had taken prenatal DHA, while children of mothers with other genotypes did not show the same boost. This is one of the cleaner examples in nutrigenetics of a gene variant predicting who actually benefits from an intervention.

What This Test Does Not Do

FADS2 genotyping is a research and exploratory marker. There are no clinical guidelines that say a particular genotype should change your medications or trigger a specific screening cascade. There is no published evidence that screening healthy people with FADS2 catches disease earlier or improves hard outcomes like heart attacks, strokes, or death. What it can do is explain why your omega-3 numbers behave the way they do, and inform how you approach diet, supplementation, and pregnancy planning.

When Results Can Be Misleading

Genetic tests carry their own kinds of confounders, distinct from blood-based markers. Keep these in mind when interpreting a FADS2 result.

• Variant panel coverage: this test only reads the specific FADS2 variants on the panel. A result that looks normal does not rule out other rare variants in the gene that the assay was not designed to detect.
• Ancestry effects: the frequency and impact of FADS2 variants differ across populations. The TT version of rs174537, for instance, is far more common in some populations than others, and the size of its effect on EPA and arachidonic acid has been studied most thoroughly in specific cohorts.
• Direct-to-consumer versus clinical-grade testing: consumer genetics platforms sometimes report FADS variants, but the accuracy, variant coverage, and interpretation rigor differ from clinical-grade tests. A consumer report should be confirmed before driving any decision.
• Single variant focus: most studies look at one or two variants at a time. Your overall fatty acid metabolism depends on the FADS2 region as a whole, plus the related FADS1 and FADS3 genes, so a single SNP is one piece of a larger picture. Many variants commonly called FADS2 variants sit just outside the gene and are inherited as a block with FADS1 and FADS3, making it hard to attribute effects to FADS2 alone.

One-Time Test, Lifetime Use

FADS2 is a fixed genetic variant. Your result will be the same in five years and in fifty. You do not need to retest the genotype itself unless there is a question about the lab's variant call, in which case a confirmatory method like Sanger sequencing can resolve it.

Where ongoing tracking matters is in the downstream measurements your genotype influences. If you carry a variant linked to lower long-chain omega-3 production, your omega-3 index is the marker that tells you whether your diet and supplementation are actually keeping you in a protective range. A reasonable rhythm: baseline omega-3 index now, retest in three to six months after any change in diet or supplements, then annually. If FADS2 variants line up with worse lipid patterns in your ancestry group, lipid panels and ApoB (apolipoprotein B) deserve the same cadence.

What to Do With an At-Risk Genotype

If your FADS2 result suggests reduced conversion of plant omega-3s to EPA and DHA, the decision pathway is straightforward but not automatic. Confirm your downstream picture: order an omega-3 index, a lipid panel including ApoB, fasting insulin, and HbA1c. If your omega-3 index is low, the studies in this field directionally support leaning on preformed EPA and DHA from fish or algae rather than expecting flax or walnut oil to do the work, though no randomized trial has tested a FADS2-genotype-guided supplementation strategy. If your lipid or glucose markers are also off-pattern, that is the time to bring in a lipidologist or a clinician comfortable with cardiometabolic genetics.

FADS2 variants are inherited, so a meaningful result is also relevant information for biological parents, siblings, and children. They share roughly half your variants and may benefit from the same diet and supplementation framing, especially during pregnancy and early childhood when long-chain fats matter most for brain development.